Table 2.
Patient characteristics of age- and sex-matched CN APOE ε4 carriers and noncarriers and age- and sex-matched elderly CN, MCI, and AD APOE ε4 carriersa
| APOE ε4 carrier N = 209 | APOE ε4 noncarrier N = 209 | CN N = 70 | MCI N = 35 | AD dementia N = 35 | |
|---|---|---|---|---|---|
| Age, y | |||||
| Median (IQR) | 76 (71, 80) | 76 (71, 80) | 80 (76, 84) | 80 (76, 83) | 80 (75, 84) |
| Min, max | 31, 91 | 31, 91 | 71, 91 | 72, 88 | 71, 92 |
| Male gender, no. (%) | 117 (56) | 117 (56) | 38 (54) | 19 (54) | 19 (54) |
| Education, y | |||||
| Median (IQR) | 14 (12, 16) | 14 (12, 16) | 14 (12, 17) | 13 (12, 16) | 16 (12, 18) |
| Min, max | 8, 20 | 8, 20 | 8, 20 | 11, 20 | 8, 20 |
| AD-signature meta-ROI FDG ratio | |||||
| Mean (SD) | 1.85 (0.2) | 1.91 (0.2) | 1.85 (0.2) | 1.78 (0.2) | 1.59 (0.2) |
| APOE ε4 carrier versus | |||||
| MCI versusb | −0.062, p = 0.10 | ||||
| AD dementia versusb | −0.255, p < 0.001 | −0.193, p < 0.001 | |||
Key: AD, Alzheimer’s disease; APOE, apolipoprotein E; CN, cognitively normal; FDG, 18F-fluorodeoxyglucose; MCI, mild cognitive impairment; PET, positron emission tomography; PiB, 11C-Pittsburgh compound B; ROI, region of interest; SUVr, standardized uptake value ratio.
a
AD dementia, MCI, and CN participants are APOE ε4 carriers and age 70 or older. AD and MCI participants are also amyloid positive by PiB PET (SUVr > 1.5).
b
Mean differences in FDG ratios in AD signature meta-ROI with p-values from t-tests.